PORTAL Registry

Portal vein Obstruction Revascularisation Therapy After Liver transplantation registr

PORTAL Registry

Portal vein Obstruction Revascularisation Therapy After Liver transplantation registr

PORTAL Registry

Portal vein Obstruction Revascularisation Therapy After Liver transplantation registr

PORTAL Registry

Portal vein Obstruction Revascularisation Therapy After Liver transplantation registr

PORTAL Registry

Portal vein Obstruction Revascularisation Therapy After Liver transplantation registr

CCDC 2143239: Experimental Crystal Structure Determination

Related Article: Daisy R. S. Pooler, Daniel Doellerer, Stefano Crespi, Ben L. Feringa|2022|Org.Chem.Front.|9|2084|doi:10.1039/D2QO00129

CCDC 2143164: Experimental Crystal Structure Determination

Related Article: Daisy R. S. Pooler, Daniel Doellerer, Stefano Crespi, Ben L. Feringa|2022|Org.Chem.Front.|9|2084|doi:10.1039/D2QO00129

MeDAS PET: a non-invasive imaging tool for quantitative assessment of myelin loss in multiple sclerosis

PET and MR imaging dataset of patients (n=10) with primary and secondary progressive multiple sclerosis.,Data categories: Imaging data, Medical records, Physiological/Biochemical measurements Material collected: Plasma, Whole Blood Experimental data: Other Number of donors: 10 Sex: Female, Male Age: 45-65 Year Diseases studied: Multiple sclerosis

CCDC 2143240: Experimental Crystal Structure Determination

Related Article: Daisy R. S. Pooler, Daniel Doellerer, Stefano Crespi, Ben L. Feringa|2022|Org.Chem.Front.|9|2084|doi:10.1039/D2QO00129

OncoLifeS

OncoLifeS Living well as Cancer Survivor. OncoLifeS comprises an infrastructure in which the clinical data (including data on risk factors and comorbidity) and biomaterials of all patients with an oncological diagnosis including follow-up are systematically recorded. The aim of the infrastructure is to facilitate research aimed to gain insight into the effects of patient characteristics, the underlying malignant disease process (both molecular biologically and clinically), the treatment on the short and long-term effects on the disease process and other organ functions. The infrastructure of the OncoLifeS oncological databiobank provides opportunities for research on the molecular biological and environmental factors that are associated with the presence of cancer, but also for research on the effectiveness of the treatment and the possible (late) unwanted side-effects. Patients with an oncological diagnosis who are treated within the UMCG after consent (Informed consent) are included, registered and followed. The intention is to collect a well-defined and limited set within the context of care for a larger group of patients. Data are collected on patient and disease characteristics, treatment, and patient reported outcome measures. Biomaterials are collected as well as follow-up data. There is an option to perform a more extensive data collection for a shorter or longer period of time. Patients with an oncological diagnosis who are treated within the UMCG after consent (Informed consent) are included, registered and followed. The intention is to collect a well-defined and limited set within the context of care for a larger group of patients. Data are collected on patient and disease characteristics, treatment, and patient reported outcome measures. Biomaterials are collected as well as follow-up data. There is an option to perform a more extensive data collection for a shorter or longer period of time.,Data categories: Biological samples, Medical records, Other Material collected: Plasma, Serum, Urine, Tissue; paraffin preserved, Tissue; cryo preserved, Other Experimental data: Not available Number of donors: 2200 Sex: Female, Male Age: >18 Year